Jarushka Ross -

You may not have seen her on a primetime talk show, but inside the walls of Dublin’s Beaumont Hospital and the global corridors of the International Association for the Study of Lung Cancer (IASLC) , she is something of a rock star. And her specialty? The most stigmatized, aggressive, and historically hopeless of all major cancers: lung cancer. Ross’s journey is not the typical tale of a straight-A student following a linear path. A graduate of Trinity College Dublin, she did something many Irish-trained doctors are afraid to do—she left the green shores for the brutal, brilliant crucible of American medicine.

Landing at the , Ross found herself at ground zero of the immunotherapy revolution. This wasn’t just chemotherapy anymore; this was teaching the body’s own immune system to see a tumor as an invader. But there was a dark side to this miracle. jarushka ross

In plain English: She figured out why the cure sometimes kills you, and how to stop it. You may not have seen her on a

She isn’t looking for a cure-all magic bullet. She is looking for control . She wants to turn lung cancer from a death sentence into a chronic illness—like diabetes or high blood pressure. Something you manage, not something you die from. Ross’s journey is not the typical tale of

Early data suggests this can cut the risk of recurrence in half for certain patients. In an era of "influencers" and viral health trends, Dr. Jarushka Ross represents the opposite: the quiet, rigorous, data-driven clinician who sits with a terrified family at 6 PM on a Friday.

While pharmaceutical reps were handing out brochures about the "power of immunotherapy," Ross was publishing landmark papers in The New England Journal of Medicine and The Lancet Oncology detailing the "when" and "how" of these toxicities. She created the first algorithms for community oncologists to manage a patient who develops sudden diabetes or a heart arrhythmia from a checkpoint inhibitor. “We can’t just turn off the immune system without turning off the fight against the cancer,” she has argued. “It’s a balance. We need to be smarter than the biology.” One of the most striking things about Ross is her refusal to let patients carry the burden of guilt. Lung cancer carries a unique shame that breast or colon cancer does not: the assumption that the patient "did it to themselves" via smoking.

While other researchers were celebrating the remission rates, Ross noticed the collateral damage. Patients whose lungs were clearing up were suddenly in emergency rooms with inflamed colons, arthritic joints, or, most frighteningly, swollen brains. This is Ross’s signature contribution to the field. She became the world’s leading expert on immune-related adverse events (irAEs) .